To date, the FDA has approved three TKIs for the treatment of HER2-positive metastatic BC (lapatinib, neratinib, and tucatinib); however, further knowledge about their applicability in the context of early HER2-positive BC is needed [57]. Here, ERBB2 is linked to breast cancer.